aTyr Pharma (LIFE) Earns Daily Media Impact Score of 0.15

News coverage about aTyr Pharma (NASDAQ:LIFE) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. aTyr Pharma earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.1675966560298 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the headlines that may have effected Accern’s scoring:

A number of equities analysts have recently weighed in on the company. Zacks Investment Research downgraded aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. aTyr Pharma currently has a consensus rating of “Hold” and an average price target of $4.81.

aTyr Pharma (NASDAQ:LIFE) remained flat at $$3.95 during trading hours on Thursday. The company had a trading volume of 16,432 shares, compared to its average volume of 29,816. The company has a current ratio of 9.49, a quick ratio of 9.49 and a debt-to-equity ratio of 0.17. The company has a market cap of $117.55 and a P/E ratio of -1.94. aTyr Pharma has a 52 week low of $2.30 and a 52 week high of $6.50.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. research analysts expect that aTyr Pharma will post -1.93 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Insider Buying and Selling by Quarter for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply